ATE483028T1 - Antikörper, die krebserkrankungen modifizieren - Google Patents

Antikörper, die krebserkrankungen modifizieren

Info

Publication number
ATE483028T1
ATE483028T1 AT06790536T AT06790536T ATE483028T1 AT E483028 T1 ATE483028 T1 AT E483028T1 AT 06790536 T AT06790536 T AT 06790536T AT 06790536 T AT06790536 T AT 06790536T AT E483028 T1 ATE483028 T1 AT E483028T1
Authority
AT
Austria
Prior art keywords
antibodies
cancer
cancer diseases
modify cancer
modify
Prior art date
Application number
AT06790536T
Other languages
English (en)
Inventor
David Young
Susan Hahn
Lisa Cechetto
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE483028T1 publication Critical patent/ATE483028T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT06790536T 2005-08-02 2006-08-01 Antikörper, die krebserkrankungen modifizieren ATE483028T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70507305P 2005-08-02 2005-08-02
PCT/CA2006/001250 WO2007014459A1 (en) 2005-08-02 2006-08-01 Cancerous disease modifying antibodies

Publications (1)

Publication Number Publication Date
ATE483028T1 true ATE483028T1 (de) 2010-10-15

Family

ID=37708515

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06790536T ATE483028T1 (de) 2005-08-02 2006-08-01 Antikörper, die krebserkrankungen modifizieren

Country Status (9)

Country Link
US (1) US7452978B2 (de)
EP (1) EP1929034B1 (de)
JP (1) JP2009507772A (de)
CN (1) CN101292042A (de)
AT (1) ATE483028T1 (de)
AU (1) AU2006275260A1 (de)
CA (1) CA2617458A1 (de)
DE (1) DE602006017240D1 (de)
WO (1) WO2007014459A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8466094B2 (en) * 2009-05-13 2013-06-18 Clearwater International, Llc Aggregating compositions, modified particulate metal-oxides, modified formation surfaces, and methods for making and using same

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4433059A (en) * 1981-09-08 1984-02-21 Ortho Diagnostic Systems Inc. Double antibody conjugate
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4828991A (en) * 1984-01-31 1989-05-09 Akzo N.V. Tumor specific monoclonal antibodies
EP0266032A1 (de) 1986-08-29 1988-05-04 Beecham Group Plc Modifiziertes fibrinolytisches Enzym
NZ222509A (en) * 1986-11-19 1993-03-26 Oncogen Hybridoma cell line producing antibodies binding to tumour-associated mucin antigen
US4861581A (en) * 1986-12-05 1989-08-29 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
IL85035A0 (en) * 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5183756A (en) * 1988-08-19 1993-02-02 The United States Of America As Represented By The Department Of Health And Human Services Monoclonal antibody (D612) having selective reactivity for gastrointestinal caricinomas and method for employing the same
US5171665A (en) * 1989-04-17 1992-12-15 Oncogen Monoclonal antibody to novel antigen associated with human tumors
DE3920358A1 (de) * 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6020145A (en) * 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
EP1400536A1 (de) * 1991-06-14 2004-03-24 Genentech Inc. Verfahren zur Herstellung humanisierter Antikörper
EP0539970B1 (de) * 1991-10-30 1999-05-26 Idemitsu Kosan Company Limited Verfahren zur Herstellung von menschlichen Lymphozyten und menschlichen Antikörpern; und so hergestellte Antikörper
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
IL105008A0 (en) * 1992-03-13 1993-07-08 Yeda Res & Dev Double transfectants of mhc genes as cellular vaccines for immunoprevention of tumor metastasis
EP0686260B1 (de) * 1993-02-05 2003-07-09 Epigen, Inc. Humanes carcinoma-antigen (hca), hca antikörper, hca immunoassays, aufzeichnungsmethoden und therapy
WO1996000084A1 (en) * 1994-06-24 1996-01-04 Torchilin Vladimir P Use of autoantibodies for tumor therapy and prophylaxis
US5783186A (en) * 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
US7256271B2 (en) 2003-01-21 2007-08-14 Arius Research Inc. Cancerous disease modifying antibodies
US6794494B1 (en) * 2003-04-14 2004-09-21 Arius Research, Inc. Cancerous disease modifying antibodies
US6180357B1 (en) 1999-10-08 2001-01-30 Arius Research, Inc. Individualized patient-specific anti-cancer antibodies
ES2309012T3 (es) * 1999-10-29 2008-12-16 Genentech, Inc. Composiciones del anticuerpo anti-psca y a sus procedimientos contra celulas cancerigenas que expresen psca.
ATE394425T1 (de) 2000-11-08 2008-05-15 Arius Res Inc Verfahren zur herstellung zytotoxischen antikörper gegen krebs
US7009040B2 (en) * 2003-01-21 2006-03-07 Arius Research, Inc. Cancerous disease modifying antibodies
WO2003086456A2 (en) * 2002-04-05 2003-10-23 Arius Research, Inc. Anti-ck18 monoclonal antibody and therapeutic and diagnostic uses thereof in cancer
US20040141914A1 (en) 2003-01-21 2004-07-22 Young David S.F. Cancerous disease modifying antibodies
US7399835B2 (en) * 2004-02-26 2008-07-15 Arius Research Inc. Cancerous disease modifying antibodies
US20050027106A1 (en) 2003-07-28 2005-02-03 Young David S. F. Cancerous disease modifying antibodies
US7348413B2 (en) 2004-02-26 2008-03-25 Arius Research Inc. Cancerous disease modifying antibodies

Also Published As

Publication number Publication date
DE602006017240D1 (de) 2010-11-11
EP1929034A1 (de) 2008-06-11
US20070031425A1 (en) 2007-02-08
AU2006275260A1 (en) 2007-02-08
US7452978B2 (en) 2008-11-18
JP2009507772A (ja) 2009-02-26
EP1929034A4 (de) 2009-07-08
WO2007014459A1 (en) 2007-02-08
CN101292042A (zh) 2008-10-22
EP1929034B1 (de) 2010-09-29
CA2617458A1 (en) 2007-02-08

Similar Documents

Publication Publication Date Title
WO2007095749A8 (en) Cytotoxicity mediation of cells evidencing surface expression of trop-2
ATE469220T1 (de) Antikörper, die krebserkrankungen modifizieren
CY1106455T1 (el) Τροποποιητικα αντισωματα καρκινικης νοσου
MX2009001015A (es) Anticuerpos modificadores de enfermedad cancerosa.
BRPI0601736A (pt) métodos de terapia adjuvante, método de cura de cáncer de mama não metastático, método de redução de reincidência de doenças, método de instrução de pacientes humanos com cáncer de mama her2-positivo não metastático, método de produção e métodos comerciais
WO2004065422A3 (en) Cancerous disease modifying antibodies
MX2009007619A (es) Anticuerpos modificadores de una enfermedad cancerigena.
WO2005012361A3 (en) Antibodies raised against colon carcinomas
MX2009007617A (es) Anticuerpos modificadores de una enfermedad cancerigena.
WO2003086456A3 (en) Anti-ck18 monoclonal antibody and therapeutic and diagnostic uses thereof in cancer
MX2009007618A (es) Anticuerpos modificadores de una enfermedad cancerigena.
BRPI0512040A (pt) composição farmacêutica, método de modificação de receptores de célula de tumor, método de aperfeiçoar seletividade alvo de anticorpos, método de tratar cáncer, kit, uso de prolina
DE60331827D1 (de) Zusammensetzungen für die radioimmuntherapie von gehirn-tumoren
ATE483028T1 (de) Antikörper, die krebserkrankungen modifizieren
MX2009011667A (es) Anticuerpos de modificacion de enfermedad cancerosa.
MX2009001292A (es) Anticuerpos modificadores de enfermedad cancerosa.
MX2009009919A (es) Anticuerpo 010207-01 modificador de la enfermedad del cancer, producido por la linea celular ar51a630.3 del hibridoma.
WO2008058380A8 (en) Cancerous disease modifying antibodies
DK1360208T3 (da) Fremgangsmåde til fremstilling af cytotoksiske anticancer-antistoffer
AR070279A1 (es) Anticuerpos modificadores de enfermedades cancerosas (cdma)
NO20091459L (no) Cancerose sykdomsmodifiserende antistoffer
BRPI0718609A8 (pt) Anticorpos modificadores de doença cancerosa.
AR072750A1 (es) Anticuerpos modificadores de enfermedades cancerosas
AR070280A1 (es) Anticuerpos monoclonales modificadores de enfermedades cancerosas (cdmab)
AR071847A1 (es) Anticuerpos monoclonales modificadores de enfermedades cancerosas

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties